Abbott (NYSE: ABT) on Friday reported positive data from studies evaluating the safety and effectiveness of its Volt Pulsed Field Ablation system for treating drug-refractory paroxysmal and persistent atrial fibrillation. The report, presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforces the Volt PFA System’s success rate for treating atrial fibrillation.
The results include 12-month findings that confirm the long-term safety and performance of the Volt PFA System. Volt also delivered strong results as a treatment option for AFib episodes that last longer than seven days, with nearly 68% of patients remaining free from additional episodes. It was found in the study that less than 6% of patients required a repeat ablation, one of the lowest rates in the industry. Last year, the Volt PFA System secured US Food and Drug Administration approval and CE Mark in Europe.
Additionally, the company presented positive results on its TactiFlex Duo Ablation Catheter, Sensor Enabled, a dual-energy, focal ablation catheter, designed to allow physicians to tailor how they deliver AFib therapy.
“The data for Volt confirms what I see firsthand in the procedure room with this next-generation PFA device. The system’s unique design enables a high degree of freedom from AFib for patients, and its impressive safety profile reduces PFA-specific complications such as hemolysis, which negatively impacts other parts of the body,” said Atul Verma of McGill University Health Centre and McGill University in Canada, who treated patients as part of the VOLT-AF IDE study.